Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Phase: N/A Priority: Normal
NCT ID: NCT06081244 Org: User:
Start: 10/10/24 End: 09/30/29 Due: 09/30/30

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Phase: N/A Priority: Normal
NCT ID: NCT05792150 Org: User:
Start: 12/07/22 End: 06/30/35 Due: 06/30/36

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01779206 Org: User:
Start: 05/31/12 End: 01/15/25 Due: 01/15/26

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01049425 Org: User:
Start: 02/05/09 End: 05/15/18 Due: 05/15/19

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Phase: N/A Priority: Normal
NCT ID: NCT02115204 Org: User:
Start: 06/30/00 End: 08/31/10 Due: 08/31/11

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05704829 Org: User:
Start: 02/05/24 End: 06/30/28 Due: 06/30/29

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

Phase: N/A Priority: Normal
NCT ID: NCT01745965 Org: User:
Start: 11/30/12 End: 01/15/25 Due: 01/15/26

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Phase: N/A Priority: Normal
NCT ID: NCT03988036 Org: User:
Start: 08/18/20 End: 05/31/22 Due: 05/31/23

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01781338 Org: User:
Start: 05/31/12 End: 01/15/25 Due: 01/15/26

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Phase: N/A Priority: Normal
NCT ID: NCT02214381 Org: User:
Start: 07/31/14 End: 01/15/25 Due: 01/15/26

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Phase: N/A Priority: Normal
NCT ID: NCT01690325 Org: User:
Start: 09/30/12 End: 11/30/16 Due: 11/30/17

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

Phase: N/A Priority: Normal
NCT ID: NCT02269813 Org: User:
Start: 04/01/15 End: 09/30/16 Due: 09/30/17

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Phase: N/A Priority: Normal
NCT ID: NCT04055493 Org: User:
Start: 07/02/19 End: 07/31/27 Due: 07/31/28

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

Phase: N/A Priority: Normal
NCT ID: NCT01817452 Org: User:
Start: 03/31/14 End: 01/15/25 Due: 01/15/26

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01891357 Org: User:
Start: 09/30/13 End: 11/16/16 Due: 11/16/17

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Phase: N/A Priority: Normal
NCT ID: NCT04565054 Org: User:
Start: 09/02/20 End: 07/31/29 Due: 07/31/30

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01815242 Org: User:
Start: 06/30/13 End: 01/15/25 Due: 01/15/26